LNG-IUS

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HysterectomyAdenomyosis

132 competitors in Hysterectomy

#DrugCompanyPhaseTrials

1

Arcoxia

Novartis

Phase 3

12

Cervidil

Pfizer

Phase 3

13

Elavil

AstraZeneca

Phase 3

14

Tylenol

KKenvue Brands

Phase 3

45

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

36

Celebrex

PPhiladelphia Eye Associates

Phase 3

27

Dilaudid

RRhodes Pharmaceuticals, L.P.

Phase 3

18

Ketalar

AAultman Health Foundation

Phase 3

19

Spravato

WWim Janssens

Phase 2

110

Depot Medroxyprogesterone Acetate

AbbVie

Phase 2

1Show 18 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adenomyosis1 trial

Adenomyosis: Genomic Mechanisms and Biological Response

Withdrawn·UUniversity of Texas Southwestern Medical Center··NCT03428854

Effectiveness1 trial

Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients

Completed·KKing Chulalongkorn Memorial Hospital·Phase 4·NCT02534688·50 enrolled

Hormone Replacement Therapy1 trial

Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).

Completed·Bayer·Phase 3·NCT00185458·394 enrolled

Hysterectomy1 trial

Hysterectomy and Levonorgestrel Releasing Intrauterine System (LNG-IUS) in the Treatment of Menorrhagia

Completed·UUniversity of Helsinki·Phase 3·NCT00966264·236 enrolled

Unspecified1 trial

LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study

Completed·Bayer·Phase 3·NCT01397097·766 enrolled

Details

Drug Info

Related News